
<u>Cite this as</u>: Lan-lan WAN, Da-qi ZHANG, Jin-nan ZHANG, Li-qun REN, 2017. Anti-hepatocarcinoma activity of TT-1, an analog of melittin, combined with interferon-α via promoting the interaction of NKG2D and MICA. *Journal of Zhejiang University-Science B (Biomedicine & Biotechnology)*, 18(6):522-531. http://dx.doi.org/10.1631/jzus.B1600369

## Anti-hepatocarcinoma activity of TT-1, an analog of melittin, combined with interferon-α via promoting the interaction of NKG2D and MICA

Key words: TT-1; IFN-α; NK cells; Hepatocarcinoma; Immunotherapy

## Research Summary

This article mainly focused on the anti-hepatocellular carcinoma effect of the combined therapy of TT-1 and IFN-α *in vitro and in vivo*, and the key effect and mechanisms were summarized as following:



- TT-1 inhibited the proliferation of liver cancer cells
- TT-1 + IFN-α suppressed the tumor growth *in vivo* though stimulating NK cells
- TT-1 increased the expression of MICA and and inhibited sMICA secretion
- TT-1 + IFN-α enhanced the cytotoxicity of NK92 cells



## Innovation points

A series of novelties about this research was shown as below:

- This study was firstly to investigate the effect of TT-1 combined IFN-α
- > TT-1 combined IFN-α suppressed the tumor growth *in vivo*
- > TT-1 not only increased the membrane MICA expression but also prevented membrane MICA from shedding as inhibitory soluble MICA
- > The activation of NK cytotoxicity was the target in TT-1 + IFN-α- induced anti-tumor effect